Can a simple drug cut blood loss in Kids' skull surgery?
NCT ID NCT02229968
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a medicine called Amicar (EACA) can reduce blood loss in children aged 2 to 36 months who need skull reconstruction for a condition called craniosynostosis. The trial involves 22 children, half receiving Amicar and half receiving a placebo (salt water). The goal is to see if Amicar decreases bleeding during surgery and reduces the need for blood transfusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amicar (epsilon-aminocaproic acid)
What this could lead to
If it works, this could provide a way to reduce blood loss and the need for blood transfusions in young children undergoing skull surgery.
What could go wrong
This is a small, early-phase trial with only 22 children, so results may not apply broadly. The drug may not significantly reduce blood loss or could cause side effects like allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRANIOSYNOSTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States